chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Blood sugar has been rising after the vaccine; Increase in soreness; Mild headache; Fatigue; A spontaneous report was received from a consumer concerning himself, a 68-year-old, male patient who received Moderna's COVID-19 vaccine (mRNA-1273) experienced increased blood sugar/Blood glucose increased, mild headache, increase in soreness/Pain and fatigue.   The patient's current condition included diabetes. Concomitant medication included insulin.  On 02 Jan 2021, approximately 2 hours prior to the onset of the symptoms, the patient received one of two planned doses of mRNA-1273 (Lot number unknown) intramuscularly in the right arm for prophylaxis of COVID-19 infection.   On 02 Jan 2021, a couple hours after his vaccine, he had a mild headache, an increase in soreness and fatigue. On 03 Jan 2021, the patient's blood sugar had been rising after receiving the vaccine. Prior to receiving the vaccine, his blood glucose was 118 and 3 hours after, his blood sugar increased and he had to increase his insulin dose. Additional treatment information was not provided.   Action taken with mRNA-1273 in response to the events was not provided.   The event, blood sugar increasing, was considered resolved at the time of this report. The outcomes of the events mild headache, increase in soreness and fatigue was not reported.; Reporter's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
Patient's primary complaint was swelling and pain, but denied redness, rash, or itching, or changes in mobility or use. It started approximately the next day after the immunizations and has remained stable with neither worsening nor improvement of symptoms.
Information has been received from a physician concerning a patient who on approximately 15-JAN-2007 was vaccinated with a dose of Zostavax. Two days after vaccination, on approximately 17-JAN-2007, the patient developed a rash on the lower extremities. It was a very specific rash, not blisters, more like a round, red circle rash. Additional information has been requested.
This spontaneous report was received from a healthcare worker refers to a patient of unknown demography. On 16-APR-2014, the patient was vaccinated with PNEUMOVAX 23 (dose, route and frequency were not reported) which was expired on 12-APR-2014. No adverse effects reported. No further AE information was available. Additional information has been requested.
Information has been received from a nurse practitioner concerning an adult female patient (age not reported) who several weeks ago, on an unspecified date, was vaccinated with a dose of Pneumococcal 23v polysaccharide vaccine (lot unknown). The patient reported to the nurse by phone that she developed an injection site reaction that included redness and local pain lasting about 2 weeks. It was reported that the patient sought unspecified medical attention. At the time of the report he patient outcome was unknown. The was no product quality complaint involved. No other information was available.
painful shot, hurt like hell going in; could barely lift arm; This case was reported by a consumer via  interactive digital media and described the occurrence of injection site pain in a patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles, pain (severe) and activities of daily living impaired (couldn't wear clothes). Previously administered products included Zostavax with an associated reaction of herpes zoster (patient got shingles after had gotten the original vaccine, but it was a very mild case).   On an unknown date, the patient received Shingrix. On an unknown date, unknown after receiving Shingrix, the patient experienced injection site pain and injected limb mobility decreased. On an unknown date, the outcome of the injection site pain and injected limb mobility decreased were recovered/resolved.   It was unknown if the reporter considered the injection site pain and injected limb mobility decreased to be related to Shingrix.  Additional details were provided as follows: The patient self reported the case. The age at vaccination was not reported. The patient received Shingrix vaccine and this was the most painful shot he/she ever had. it hurt like hell going in, and patient could barely lift his/her arm for several days. The druggist said everyone said the same thing. However, having had shingles before patient got the first/old vaccine, have to say he/she would amputate arm to keep from getting that again. The patient stated that the original shingles vaccine, Zostavax, was a single shot. It was no longer available in the United States and had been replaced by a two dose regimen, Shingrix, give 2 to 6 months apart. If you had the Zostavax, you should talk to your doctor and consider getting the newer, more effective Shingrix. Studies show protection begins to wane after four years, but they haven't made a definite recommendation in revaccinating that patient can find talk to his/her doctor about it. The follow up would not be possible as no contact details were available.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021AMR201449:same reporter
Red rash; Itching; Warm to the touch; This spontaneous case was reported by a consumer and describes the occurrence of RASH ERYTHEMATOUS (Red rash), PRURITUS (Itching) and INJECTION SITE WARMTH (Warm to the touch) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 006M20A) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 25-Feb-2021, the patient experienced RASH ERYTHEMATOUS (Red rash), PRURITUS (Itching) and INJECTION SITE WARMTH (Warm to the touch). The patient was treated with PRAMOCAINE HYDROCHLORIDE, ZINC ACETATE (CALADRYL CLEAR) for Itching, at an unspecified dose and frequency. On 26-Feb-2021, PRURITUS (Itching) and INJECTION SITE WARMTH (Warm to the touch) had resolved. At the time of the report, RASH ERYTHEMATOUS (Red rash) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications were not reported   Reporter did not allow further contact
I felt like I had the flu. I had chills, shaking. It lasted about 2 days.
Generalized Body Pain; Sore right injection site arm; This spontaneous case was reported by a consumer and describes the occurrence of PAIN (Generalized Body Pain) and MYALGIA (Sore right injection site arm) in a 52-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 026B21A) for COVID-19 vaccination.     Concomitant products included ABATACEPT (ORENCIA), PREDNISONE, AZITHROMYCIN (AZO), ESTROGENS CONJUGATED (PREMARIN), LISINOPRIL, AMITRIPTYLINE, AMINO ACIDS NOS (PROTINEX) and VALACICLOVIR HYDROCHLORIDE (VALACYCLOVIR HCL) for an unknown indication.    On 02-Apr-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 03-Apr-2021,  after starting mRNA-1273 (Moderna COVID-19 Vaccine), the patient experienced MYALGIA (Sore right injection site arm). On 11-Apr-2021, the patient experienced PAIN (Generalized Body Pain). On 05-Apr-2021, MYALGIA (Sore right injection site arm) had resolved. On 15-Apr-2021, PAIN (Generalized Body Pain) had resolved.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.   For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No treatment medications were reported.
Itching skin, numbness and tingling of lips and tongue Treated with 50mg Benadryl IM  Pt stable after sleeping in doctors office for approximately an hour
vaccine reaction started 12/27/2020  muscle aches on left side of body, both left arm and leg, can only say it is what I would imagine restless leg syndrome might feel like, weak and achy that disrupted sleep all night. 12/28/20 noticed enlarged lymph node on left side near clavicle tender to touch
Information has been received from a certified medical assistant concerning a 21 month-old white male with no medical history and no known drug allergies who on 11-Aug-2003 was vaccinated subcutaenously with a first dose of varicella virus vaccine live (Lot #644721/0018N). On 11-Aug-2003, concomitant medication included a subcutaneous first dose of measles virus vaccine live (+) mumps virus vaccine live (+) rubella virus vaccine live (Lot #644585/1015M), (previously reported as there was no concomitant medication). There was no illness at the time of vaccination. On 25-Oct-2003, the patient was seen with a rash on the trunk of 10-20 scattered papules that the doctor believed was chickenpox. It was also noted that the child had a stuffy nose also described as congestion. There was no prescription drug treatment required. Unspecified medical attention was sought. It was noted that the patient had recovered. There was no product quality complaint involved. No further information is requested.
Given flu and pneumonia immunization at 11:50 AM and as soon as reached car at 11:55 felt "funny and flushed". Laid pt down temp 99, BP 140/94, pulse 92. Skin dry and occ loose cough. States he "has a little bug in his chest this morning". At 12:05 feeling better, BP 148/94, temp 98.4. 12:10 AM Walked to car, wife driving, to take to Dr. or ER if worse.  12/4/12. Saw Dr this AM, chilled most of night, sleeping now. 12/11/12 Feeling better but felt "bad" for a few days.
1 week later swollen hard ball in the area of injection and it is very itchy. Extreme fatigue
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from a non-contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 48-year-old female patient (not pregnant) received BNT162b2 (BNT162B2), as dose number unknown, single (Batch/Lot number: unknown), in left arm for covid-19 immunisation. The patient's relevant medical history included: "Ankylosing spondylitis" (unspecified if ongoing); "Known allergies: PCN" (unspecified if ongoing). The patient's concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant) all with onset Dec2022, outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (2022) Positive. Therapeutic measures were taken as a result of drug ineffective, covid-19 which included Paxlovid from 26Dec2022 to 30Dec2022.  No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
My injection site is red and is sore.; My injection site is sore.; This case was reported by a consumer via interactive digital media and described the occurrence of injection site erythema in a patient who received Herpes zoster (Shingrix) for prophylaxis.   In February 2022, the patient received 1st dose of Shingrix. In February 2022, less than a week after receiving Shingrix, the patient experienced injection site erythema and injection site pain. On an unknown date, the outcome of the injection site erythema and injection site pain were Not Recovered/Not Resolved.   It was unknown if the reporter considered the injection site erythema and injection site pain to be related to Shingrix.  Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient's injection site was red and sore.  The day of reporting was the 3rd day after receiving the injection. The patient asked was this normal. The reporter asked should the patient be concerned about getting the second injection. The follow-up would not possible as no contact details were available.
Pt exp swelling w/pain @ inject site p/recvd Td; Also devel numb, painful tingling sensation involving lt arm, chest, shoulder, neck, elbow & forearm; Diffuse weakness of lt upper extremity & sensory loss C8; poss brachial plexus neuritis;
Diarrhea; a rash on my left arm and shoulder; itchiness; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 78-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Dec2022 as dose 5 (booster), single (Lot number: GJ6739) at the age of 78 years for covid-19 immunisation. The patient's relevant medical history included: "Diabetic" (unspecified if ongoing), notes: Diabetic; "Blood pressure high" (unspecified if ongoing). The patient took concomitant medications. Vaccination history included: Covid-19 vaccine (Dose 1, unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Dose 2, unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Dose 3, unknown manufacturer), for COVID-19 immunization; Covid-19 vaccine (Dose 4, unknown manufacturer), for COVID-19 immunization. The following information was reported: DIARRHOEA (non-serious) with onset Dec2022, outcome "unknown", described as "Diarrhea"; RASH (non-serious) with onset Dec2022, outcome "unknown", described as "a rash on my left arm and shoulder"; PRURITUS (non-serious) with onset Dec2022, outcome "unknown", described as "itchiness". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were not taken as a result of diarrhoea, rash, pruritus.  Additional information: Case narrative including clinical course, therapeutic measures, outcome and additional relevant information. The report not related to a study or programme. Other Conditions was yes. Investigations were reported as yes. Reason for no lot number of COVID-19 Bivalent Vaccine: Other: Consumer stated, reporter think the LOT# is GJ6739. Expiry Date of COVID-19 Bivalent Vaccine was unknown.Reporter received patient fifth Pfizer shot (later clarified ad Pfizer COVID-19 Bivalent Vaccine) at the, Thursday, 08Dec2022 and patient had a reaction. Patient believe it is a reaction and diarrhea, a rash on my left arm and shoulder, itchiness. What can patient do, what can patient take to alleviate this. Consumer was informed about the role of Pfizer Drug Safety and also informed that Pfizer Medical Information is the right department to answer the question. In response to file a safety report, Consumer stated as yes, go ahead. Reporter stated, patient think the LOT# is GJ6739. It is the Pfizer Bivalent (clarified) and it was 08Dec2022. It is the fifth shot. Any prior vaccinations (within 4 weeks) was reporter stated was no. Other medical conditions and Concomitant medications: Consumer stated, Patient was a diabetic. Patient have high blood pressure and sugar diabetes. Treatment for the medical conditions consumer stated was yes. Name of the medications patient stated was no, not at this time. Reporter stated was yes, Thursday patient had blood drawn at the. Results of the test: Consumer stated, patient don't have the results. It went straight to the doctor. Treatment in response to adverse event was no. Reassurance was stated, not at this time.
Mother reports dtr had seizure 8/30 7:30AM, it lasted 1-2min then had another seizure at 5:30AM 8/30 Then they took child to ER at hospital. Temp at ER was AM 102.4 (axillary). Parent had used Motrin after shots on 8/29/05. ER diagnosis febrile seizures.
genetic mutation; Essential Thrombocythemia; This is a spontaneous report from a contactable consumer (patient).  A 57-year-old female patient received the second dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE), via an unspecified route of administration, administered in the left arm on 16Apr2021 13:00 (Batch/Lot Number: ER8737) as DOSE 2, SINGLE for covid-19 immunisation.  Medical history was reported none. The patient had no known allergies. Concomitant medication included ethinylestradiol, norethisterone acetate (FYAVOLV) taken for an unspecified indication, start and stop date were not reported. The patient was not pregnant at time of vaccination. The vaccine was administered in a pharmacy or drug store. There were no other vaccine received in four weeks. The patient had no COVID-19 prior vaccination.  Historical vaccine included the first dose of BNT162B2  an unspecified route of administration, administered in the right arm on 24Mar2021 13:00 (Batch/Lot Number: EP7534) as DOSE 1, SINGLE for covid-19 immunization. On 01Jul2021 12:00, the patient experienced essential thrombocythemia (medically significant). It was reported that approximately 2.5 months after receiving her second dose of Pfizer Covid-19, patient's blood results showed an alarmingly high platelet count and she had to see a hemotologist who ultimately diagnosed it as essential thrombocythemia, which could be caused by a genetic mutation (unspecified date). The timing made her concerned that possibly the vaccine had triggered this condition, which the patient now had to take medication for the rest of her life. The events resulted in doctor or other healthcare professional office/clinic visit. As treatment, the patient was prescribed hydroxyurea medication. The patient had not been tested for COVID-19 post vaccination. The outcome of the events was recovered with sequelae.   Follow-up attempts are completed. No further information is expected.
Later on the day that I received the SHINGRIX vaccine, I experienced malaise, then flu like symptoms such as muscle/bone aches all over my body, vomiting, multiple episodes (10-12) of diarrhea, and major headache. The following morning I took a ZOMIG 5mg (for the HA), 2 IMODIUM, and over the day finished 2 quarts of Pedialyte (as I am prone to electrolyte imbalance following the diarrhea). I had the flu vaccine through work. Although weak, I was much better by Saturday evening.
Left leg (lower thigh) red, feverish, itching, swollen, felt nodular lesion. Cool compresses, Nuzon Gel-apply BID. Mom gave Motrin.
This spontaneous report as received from a healthcare worker refers to a 15 year old female patient. On 15-AUG-2003 the patient was vaccinated with the first dose of VARIVAX (Merck) (dose, route and Lot# were not reported). On 29-JUN-2015, the patient was intended to receive her second dose of VARIVAX (Merck) but received a dose of ZOSTAVAX (Lot#K016320, expiration date 24-DEC-2015) in error. Additional information has been requested.
No additional AE/PQC; patient was given a dose of VAQTA after the dose was stored improperly.; This spontaneous report was received from a medical assistant concerning a patient of unknown age and gender. The patient's medical history, concurrent conditions, and concomitant therapies were not reported.   On 02-MAY-2023, the patient was vaccinated with an improperly stored dose of Hepatitis A Vaccine, Inactivated (VAQTA) intramuscular injection, 0.5 ml (series), lot # x003791, expiration date 01-JUN-2024, as prophylaxis (injection anatomical location, and route of administration were not provided) (Product storage error). The improperly stored vaccine underwent a temperature excursion for 7 hours at 34-degree Fahrenheit. It was unknown if there were any previous excursions. No additional adverse events or product quality complaint (PQC) were reported (No adverse event).
This case was reported by a consumer via call center representative and described the occurrence of trouble falling asleep in a male patient who received Herpes zoster (Shingrix) for prophylaxis. On 27th December 2021, the patient received the 2nd dose of Shingrix. In December 2021, less than a week after receiving Shingrix, the patient experienced trouble falling asleep, appetite absent, fever, dizziness and nausea. On an unknown date, the outcome of the trouble falling asleep, appetite absent, fever, dizziness and nausea were not recovered/not resolved. It was unknown if the reporter considered the trouble falling asleep, appetite absent, fever, dizziness and nausea to be related to Shingrix. Additional details were provided as follows: The patient self-reported this case. The age at vaccination was not reported. The patient reported that he was experiencing nausea, dizziness, fever, no appetite, and cannot fall asleep. Moreover, the patient reported that his healthcare professional was in the process of calling a prescription for sleep aid. The symptoms were on going and had not resolved. Very limited information was provided. The patient was rushing, and he was being rushed by his family member as well to disconnect the call. Due to the reporter rushing to disconnect the call, could not get details information and a consent to follow-up with healthcare professional. Therefore, healthcare professional contact information was not collected.
Tested positive for COVID-19 with a home COVID-19 test; Also had an intense sore throat that wasn't getting better, so my doctor tested me for Strep throat and I tested positive; Was prescribed PAXLOVID; took another home COVID-19 test and it was negative.
Around one hour after my second moderna vaccine for COVID-19, the arm in which I received the injection became sore, inflamed, and red. Within hours, a knot formed at the injection site as well. The area was about the size of my hand.  I put ice on it several times a day for about 3 days until the pain went away. At that time, my arm remained inflamed, red, and became itchy. This lasted for 3 weeks until it finally went away completely, 3.5 weeks after my injection.
Patient came back to the pharmacy at 5:40pm saying that she had a rash at the injection site. She stated that she the site was itchy and red.
Abdominal pain, loose stools, light headedness, upper extremity weakness and slight confusion. Symptoms lasted 16 hours. recipient contacted PMD . Nurse called back and advised rest, bland diet , water and Gatorade for hydration for rest of weekend and to contact if worsening of symptoms or no improvement. Recipient reported that she recovered completely within 16 to 24 hours after onset of symptoms.
Reported 10/25/10: On-going sore arm, episodic electric type pain radiating to left trapezius and down arm. Previous flu shots with localized tenderness only.
22MAY94 pt began to have problems w/equilibrium-falling over alot; had a fever on 21MAY94; was woozy for 3 days-wouldn't eat & slept alot; very fussy when touched; dx as acute ataxic febrile illness w/residual ataxia secondary to encephalop
Pt recvd vax approx 420PM stating pt had a convuls witness by grandma @ home approx 10 mins ago; pt alert, trembling, lips & nailbed blue; t103.8 ax; HR 120; pt given Tempra;
Day of shot on January 3, 2019 she left doctors and said she felt tired. Later she said she was very sleepy and didn't want to go to softball practice that day. She went to bed. Woke up around midnight throwing up. I thought she had the flu. Didn't go to school rest of week. and missed most days after. Woke up every more with head in the toilet being sick. Was very nausea and complained of feeling like she was run down. After a few weeks of this we started having test.
Pt got "hot flashes" and felt faint and had to sit down for about half an hour.
Pt was running around for a few minutes and then all of a sudden fainted to the floor, fell on her face.  She was unresponsive for a minute and jerky movements of her feet were noted.
Next morning I woke up with a sore upper left arm that carried through until around noon on Friday, 3/12/21.
3/28 - Vaccine administered. 3/29 - Mild swelling (left upper arm). 3/30 - Mild swelling, tenderness to palpation, erythema and petechiae -  DURICEF prescribed for 7 days.
Vaccine was administered in the left arm. Swollen lymph nodes on left side on body in the armpit and neck.  Welts at and around the injection site about 2 inches across.  Nausea, dizziness, and headache. Possible abscess at the injection site.